{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T02:14:43Z","timestamp":1792808083232,"version":"4.5.0"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,2,27]],"date-time":"2025-02-27T00:00:00Z","timestamp":1740614400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,2,27]],"date-time":"2025-02-27T00:00:00Z","timestamp":1740614400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Cancer"],"DOI":"10.1038\/s43018-025-00922-5","type":"journal-article","created":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T12:47:26Z","timestamp":1740746846000},"page":"432-444","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Neoadjuvant cabozantinib for locally advanced nonmetastatic clear cell renal cell carcinoma: a phase 2 trial"],"prefix":"10.1038","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4003-1103","authenticated-orcid":false,"given":"Mehmet A.","family":"Bilen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-5179-1889","authenticated-orcid":false,"given":"BaoHan T.","family":"Vo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8926-3058","authenticated-orcid":false,"given":"Yuan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3139-5079","authenticated-orcid":false,"given":"Rachel","family":"Greenwald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amir H.","family":"Davarpanah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3742-9594","authenticated-orcid":false,"given":"Donald","family":"McGuire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rakesh","family":"Shiradkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-9064-2456","authenticated-orcid":false,"given":"Liping","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adhishek","family":"Midya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bassel","family":"Nazha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacqueline T.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sierra","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wilena","family":"Session","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Greta","family":"Russler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Caulfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shreyas S.","family":"Joshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3731-4209","authenticated-orcid":false,"given":"Vikram M.","family":"Narayan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher P.","family":"Filson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth","family":"Ogan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omer","family":"Kucuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bradley Curtis","family":"Carthon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luke","family":"Del Balzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Athena","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriana","family":"Boyanton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nataliya","family":"Prokhnevska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8566-9576","authenticated-orcid":false,"given":"Maria Andrea","family":"Cardenas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ewelina","family":"Sobierajska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9128-2004","authenticated-orcid":false,"given":"Caroline S.","family":"Jansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dattatraya H.","family":"Patil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edouard","family":"Nicaise","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5712-8134","authenticated-orcid":false,"given":"Adeboye O.","family":"Osunkoya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7624-5598","authenticated-orcid":false,"given":"Haydn T.","family":"Kissick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7251-142X","authenticated-orcid":false,"given":"Viraj A.","family":"Master","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,27]]},"reference":[{"key":"922_CR1","doi-asserted-by":"publisher","first-page":"79","DOI":"10.14740\/wjon1279","volume":"11","author":"SA Padala","year":"2020","unstructured":"Padala, S. A. et al. Epidemiology of renal cell carcinoma. World J. Oncol. 11, 79\u201387 (2020).","journal-title":"World J. Oncol."},{"key":"922_CR2","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray, F. et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 68, 394\u2013424 (2018).","journal-title":"CA Cancer J. Clin."},{"key":"922_CR3","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1016\/j.juro.2013.12.046","volume":"191","author":"SC King","year":"2014","unstructured":"King, S. C., Pollack, L. A., Li, J., King, J. B. & Master, V. A. Continued increase in incidence of renal cell carcinoma, especially in young patients and high grade disease: United States 2001 to 2010. J. Urol. 191, 1665\u20131670 (2014).","journal-title":"J. Urol."},{"key":"922_CR4","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3322\/caac.21820","volume":"74","author":"RL Siegel","year":"2024","unstructured":"Siegel, R. L., Giaquinto, A. N. & Jemal, A. Cancer statistics, 2024. CA Cancer J. Clin. 74, 12\u201349 (2024).","journal-title":"CA Cancer J. Clin."},{"key":"922_CR5","doi-asserted-by":"publisher","first-page":"71","DOI":"10.6004\/jnccn.2022.0001","volume":"20","author":"RJ Motzer","year":"2022","unstructured":"Motzer, R. J. et al. Kidney Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology. J. Natl Compr. Canc. Netw. 20, 71\u201390 (2022).","journal-title":"J. Natl Compr. Canc. Netw."},{"key":"922_CR6","doi-asserted-by":"publisher","first-page":"2044","DOI":"10.1016\/j.juro.2009.01.043","volume":"181","author":"V Margulis","year":"2009","unstructured":"Margulis, V., McDonald, M., Tamboli, P., Swanson, D. A. & Wood, C. G. Predictors of oncological outcome after resection of locally recurrent renal cell carcinoma. J. Urol. 181, 2044\u20132051 (2009).","journal-title":"J. Urol."},{"key":"922_CR7","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1056\/NEJMoa2106391","volume":"385","author":"TK Choueiri","year":"2021","unstructured":"Choueiri, T. K. et al. Adjuvant pembrolizumab after nephrectomy in renal-cell carcinoma. N. Engl. J. Med. 385, 683\u2013694 (2021).","journal-title":"N. Engl. J. Med."},{"key":"922_CR8","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1038\/s41591-023-02336-1","volume":"29","author":"C Garbe","year":"2023","unstructured":"Garbe, C. et al. Neoadjuvant immunotherapy for melanoma is now ready for clinical practice. Nat. Med. 29, 1310\u20131312 (2023).","journal-title":"Nat. Med."},{"key":"922_CR9","doi-asserted-by":"publisher","first-page":"2298","DOI":"10.1158\/1535-7163.MCT-11-0264","volume":"10","author":"FM Yakes","year":"2011","unstructured":"Yakes, F. M. et al. Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth. Mol. Cancer Ther. 10, 2298\u20132308 (2011).","journal-title":"Mol. Cancer Ther."},{"key":"922_CR10","doi-asserted-by":"publisher","first-page":"1814","DOI":"10.1056\/NEJMoa1510016","volume":"373","author":"TK Choueiri","year":"2015","unstructured":"Choueiri, T. K. et al. Cabozantinib versus everolimus in advanced renal-cell carcinoma. N. Engl. J. Med. 373, 1814\u20131823 (2015).","journal-title":"N. Engl. J. Med."},{"key":"922_CR11","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1056\/NEJMoa2026982","volume":"384","author":"TK Choueiri","year":"2021","unstructured":"Choueiri, T. K. et al. Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma. N. Engl. J. Med. 384, 829\u2013841 (2021).","journal-title":"N. Engl. J. Med."},{"key":"922_CR12","doi-asserted-by":"publisher","first-page":"2449","DOI":"10.1158\/1078-0432.CCR-21-2517","volume":"28","author":"R Esteban-Fabro","year":"2022","unstructured":"Esteban-Fabro, R. et al. Cabozantinib enhances anti-PD1 activity and elicits a neutrophil-based immune response in hepatocellular carcinoma. Clin. Cancer Res. 28, 2449\u20132460 (2022).","journal-title":"Clin. Cancer Res."},{"key":"922_CR13","doi-asserted-by":"publisher","first-page":"1746","DOI":"10.1136\/gutjnl-2020-320716","volume":"70","author":"R Shang","year":"2021","unstructured":"Shang, R. et al. Cabozantinib-based combination therapy for the treatment of hepatocellular carcinoma. Gut 70, 1746\u20131757 (2021).","journal-title":"Gut"},{"key":"922_CR14","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1158\/2159-8290.CD-16-0778","volume":"7","author":"A Patnaik","year":"2017","unstructured":"Patnaik, A. et al. Cabozantinib eradicates advanced murine prostate cancer by activating antitumor innate immunity. Cancer Discov. 7, 750\u2013765 (2017).","journal-title":"Cancer Discov."},{"key":"922_CR15","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1038\/nature21676","volume":"543","author":"X Lu","year":"2017","unstructured":"Lu, X. et al. Effective combinatorial immunotherapy for castration-resistant prostate cancer. Nature 543, 728\u2013732 (2017).","journal-title":"Nature"},{"key":"922_CR16","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1111\/cas.13906","volume":"110","author":"Y Yamamoto","year":"2019","unstructured":"Yamamoto, Y. et al. Clinical significance of the mutational landscape and fragmentation of circulating tumor DNA in renal cell carcinoma. Cancer Sci. 110, 617\u2013628 (2019).","journal-title":"Cancer Sci."},{"key":"922_CR17","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1016\/j.eururo.2017.03.046","volume":"72","author":"SK Pal","year":"2017","unstructured":"Pal, S. K. et al. Evolution of circulating tumor DNA profile from first-line to subsequent therapy in metastatic renal cell carcinoma. Eur. Urol. 72, 557\u2013564 (2017).","journal-title":"Eur. Urol."},{"key":"922_CR18","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1634\/theoncologist.2016-0229","volume":"22","author":"SM Tolaney","year":"2017","unstructured":"Tolaney, S. M. et al. Phase II and biomarker study of cabozantinib in metastatic triple-negative breast cancer patients. Oncologist 22, 25\u201332 (2017).","journal-title":"Oncologist"},{"key":"922_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.lungcan.2019.06.020","volume":"135","author":"M Khorrami","year":"2019","unstructured":"Khorrami, M. et al. Predicting pathologic response to neoadjuvant chemoradiation in resectable stage III non-small cell lung cancer patients using computed tomography radiomic features. Lung Cancer 135, 1\u20139 (2019).","journal-title":"Lung Cancer"},{"key":"922_CR20","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-017-0846-1","volume":"19","author":"NM Braman","year":"2017","unstructured":"Braman, N. M. et al. Intratumoral and peritumoral radiomics for the pretreatment prediction of pathological complete response to neoadjuvant chemotherapy based on breast DCE-MRI. Breast Cancer Res. 19, 57 (2017).","journal-title":"Breast Cancer Res."},{"key":"922_CR21","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1200\/EDBK_199747","volume":"38","author":"K Bera","year":"2018","unstructured":"Bera, K., Velcheti, V. & Madabhushi, A. Novel quantitative imaging for predicting response to therapy: techniques and clinical applications. Am. Soc. Clin. Oncol. Educ. Book 38, 1008\u20131018 (2018).","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"922_CR22","doi-asserted-by":"publisher","first-page":"314","DOI":"10.5306\/wjco.v13.i5.314","volume":"13","author":"C Aguado","year":"2022","unstructured":"Aguado, C. et al. Neoadjuvant treatment in non-small cell lung cancer: new perspectives with the incorporation of immunotherapy. World J. Clin. Oncol. 13, 314\u2013322 (2022).","journal-title":"World J. Clin. Oncol."},{"key":"922_CR23","doi-asserted-by":"publisher","first-page":"2696","DOI":"10.21037\/tlcr-2020-63","volume":"9","author":"W Liang","year":"2020","unstructured":"Liang, W. et al. Expert consensus on neoadjuvant immunotherapy for non-small cell lung cancer. Transl. Lung Cancer Res. 9, 2696\u20132715 (2020).","journal-title":"Transl. Lung Cancer Res."},{"key":"922_CR24","doi-asserted-by":"publisher","first-page":"2144","DOI":"10.1158\/1078-0432.CCR-18-1449","volume":"25","author":"KH Kim","year":"2019","unstructured":"Kim, K. H. et al. The first-week proliferative response of peripheral blood PD-1(+)CD8(+) T cells predicts the response to anti-PD-1 therapy in solid tumors. Clin. Cancer Res. 25, 2144\u20132154 (2019).","journal-title":"Clin. Cancer Res."},{"key":"922_CR25","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1038\/nature22079","volume":"545","author":"AC Huang","year":"2017","unstructured":"Huang, A. C. et al. T-cell invigoration to tumour burden ratio associated with anti-PD-1 response. Nature 545, 60\u201365 (2017).","journal-title":"Nature"},{"key":"922_CR26","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1038\/s41591-019-0357-y","volume":"25","author":"AC Huang","year":"2019","unstructured":"Huang, A. C. et al. A single dose of neoadjuvant PD-1 blockade predicts clinical outcomes in resectable melanoma. Nat. Med. 25, 454\u2013461 (2019).","journal-title":"Nat. Med."},{"key":"922_CR27","doi-asserted-by":"publisher","first-page":"4993","DOI":"10.1073\/pnas.1705327114","volume":"114","author":"AO Kamphorst","year":"2017","unstructured":"Kamphorst, A. O. et al. Proliferation of PD-1+ CD8 T cells in peripheral blood after PD-1-targeted therapy in lung cancer patients. Proc. Natl Acad. Sci. USA 114, 4993\u20134998 (2017).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"922_CR28","doi-asserted-by":"publisher","unstructured":"Carlisle, J. W. et al. Clinical outcome following checkpoint therapy in renal cell carcinoma is associated with a burst of activated CD8 T cells in blood. J. Immunother. Cancer https:\/\/doi.org\/10.1136\/jitc-2022-004803 (2022).","DOI":"10.1136\/jitc-2022-004803"},{"key":"922_CR29","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1038\/s41586-019-1836-5","volume":"576","author":"CS Jansen","year":"2019","unstructured":"Jansen, C. S. et al. An intra-tumoral niche maintains and differentiates stem-like CD8 T cells. Nature 576, 465\u2013470 (2019).","journal-title":"Nature"},{"key":"922_CR30","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.immuni.2022.12.002","volume":"56","author":"N Prokhnevska","year":"2023","unstructured":"Prokhnevska, N. et al. CD8(+) T cell activation in cancer comprises an initial activation phase in lymph nodes followed by effector differentiation within the tumor. Immunity 56, 107\u2013124 e105 (2023).","journal-title":"Immunity"},{"key":"922_CR31","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1016\/j.cell.2018.10.038","volume":"175","author":"M Sade-Feldman","year":"2018","unstructured":"Sade-Feldman, M. et al. Defining T cell states associated with response to checkpoint immunotherapy in melanoma. Cell 175, 998\u20131013 e1020 (2018).","journal-title":"Cell"},{"key":"922_CR32","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1038\/s41590-019-0312-6","volume":"20","author":"BC Miller","year":"2019","unstructured":"Miller, B. C. et al. Subsets of exhausted CD8(+) T cells differentially mediate tumor control and respond to checkpoint blockade. Nat. Immunol. 20, 326\u2013336 (2019).","journal-title":"Nat. Immunol."},{"key":"922_CR33","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1038\/nature19330","volume":"537","author":"SJ Im","year":"2016","unstructured":"Im, S. J. et al. Defining CD8+ T cells that provide the proliferative burst after PD-1 therapy. Nature 537, 417\u2013421 (2016).","journal-title":"Nature"},{"key":"922_CR34","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.immuni.2018.11.014","volume":"50","author":"S Kurtulus","year":"2019","unstructured":"Kurtulus, S. et al. Checkpoint blockade immunotherapy induces dynamic changes in PD-1(-)CD8(+) tumor-infiltrating T cells. Immunity 50, 181\u2013194 e186 (2019).","journal-title":"Immunity"},{"key":"922_CR35","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.immuni.2018.12.021","volume":"50","author":"I Siddiqui","year":"2019","unstructured":"Siddiqui, I. et al. Intratumoral Tcf1(+)PD-1(+)CD8(+) T cells with stem-like properties promote tumor control in response to vaccination and checkpoint blockade immunotherapy. Immunity 50, 195\u2013211 e110 (2019).","journal-title":"Immunity"},{"key":"922_CR36","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1016\/j.juro.2008.10.001","volume":"181","author":"AA Thomas","year":"2009","unstructured":"Thomas, A. A. et al. Response of the primary tumor to neoadjuvant sunitinib in patients with advanced renal cell carcinoma. J. Urol. 181, 518\u2013523 (2009). discussion 523.","journal-title":"J. Urol."},{"key":"922_CR37","doi-asserted-by":"publisher","first-page":"2431","DOI":"10.1158\/1078-0432.CCR-07-4089","volume":"14","author":"AA van der Veldt","year":"2008","unstructured":"van der Veldt, A. A. et al. Sunitinib for treatment of advanced renal cell cancer: primary tumor response. Clin. Cancer Res. 14, 2431\u20132436 (2008).","journal-title":"Clin. Cancer Res."},{"key":"922_CR38","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1016\/j.juro.2010.05.041","volume":"184","author":"NJ Hellenthal","year":"2010","unstructured":"Hellenthal, N. J. et al. Prospective clinical trial of preoperative sunitinib in patients with renal cell carcinoma. J. Urol. 184, 859\u2013864 (2010).","journal-title":"J. Urol."},{"key":"922_CR39","doi-asserted-by":"publisher","first-page":"112 e115","DOI":"10.1016\/j.urolonc.2014.11.009","volume":"33","author":"BR Lane","year":"2015","unstructured":"Lane, B. R. et al. Presurgical sunitinib reduces tumor size and may facilitate partial nephrectomy in patients with renal cell carcinoma. Urol. Oncol. 33, 112 e115\u2013112 e121 (2015).","journal-title":"Urol. Oncol."},{"key":"922_CR40","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1038\/s41416-022-01883-7","volume":"127","author":"GD Stewart","year":"2022","unstructured":"Stewart, G. D. et al. A Phase II study of neoadjuvant axitinib for reducing the extent of venous tumour thrombus in clear cell renal cell cancer with venous invasion (NAXIVA). Br. J. Cancer 127, 1051\u20131060 (2022).","journal-title":"Br. J. Cancer"},{"key":"922_CR41","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1200\/JCO.2009.24.7759","volume":"28","author":"CL Cowey","year":"2010","unstructured":"Cowey, C. L. et al. Neoadjuvant clinical trial with sorafenib for patients with stage II or higher renal cell carcinoma. J. Clin. Oncol. 28, 1502\u20131507 (2010).","journal-title":"J. Clin. Oncol."},{"key":"922_CR42","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1016\/j.eururo.2014.01.035","volume":"66","author":"JA Karam","year":"2014","unstructured":"Karam, J. A. et al. Phase 2 trial of neoadjuvant axitinib in patients with locally advanced nonmetastatic clear cell renal cell carcinoma. Eur. Urol. 66, 874\u2013880 (2014).","journal-title":"Eur. Urol."},{"key":"922_CR43","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1111\/bju.14581","volume":"123","author":"C Lebacle","year":"2019","unstructured":"Lebacle, C. et al. Evaluation of axitinib to downstage cT2a renal tumours and allow partial nephrectomy: a phase II study. BJU Int. 123, 804\u2013810 (2019).","journal-title":"BJU Int."},{"key":"922_CR44","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.euo.2021.04.002","volume":"5","author":"MA Gorin","year":"2022","unstructured":"Gorin, M. A. et al. Neoadjuvant nivolumab in patients with high-risk nonmetastatic renal cell carcinoma. Eur. Urol. Oncol. 5, 113\u2013117 (2022).","journal-title":"Eur. Urol. Oncol."},{"key":"922_CR45","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1016\/j.eururo.2022.01.043","volume":"81","author":"MI Carlo","year":"2022","unstructured":"Carlo, M. I. et al. Phase II study of neoadjuvant nivolumab in patients with locally advanced clear cell renal cell carcinoma undergoing nephrectomy. Eur. Urol. 81, 570\u2013573 (2022).","journal-title":"Eur. Urol."},{"key":"922_CR46","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1056\/NEJMoa2312695","volume":"390","author":"TK Choueiri","year":"2024","unstructured":"Choueiri, T. K. et al. Overall survival with adjuvant pembrolizumab in renal-cell carcinoma. N. Engl. J. Med. 390, 1359\u20131371 (2024).","journal-title":"N. Engl. J. Med."},{"key":"922_CR47","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1016\/S1470-2045(22)00278-9","volume":"23","author":"N Agarwal","year":"2022","unstructured":"Agarwal, N. et al. Cabozantinib in combination with atezolizumab in patients with metastatic castration-resistant prostate cancer: results from an expansion cohort of a multicentre, open-label, phase 1b trial (COSMIC-021). Lancet Oncol. 23, 899\u2013909 (2022).","journal-title":"Lancet Oncol."},{"key":"922_CR48","doi-asserted-by":"publisher","unstructured":"Verzoni, E. et al. Potent natural killer (NK) and myeloid blood cell remodeling by cabozantinib (Cabo) in pre-treated metastatic renal cell carcinoma (mRCC) patients (pts). Ann. Oncol. https:\/\/doi.org\/10.1093\/annonc\/mdy283.091 (2018).","DOI":"10.1093\/annonc\/mdy283.091"},{"key":"922_CR49","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1016\/S1470-2045(20)30202-3","volume":"21","author":"AB Apolo","year":"2020","unstructured":"Apolo, A. B. et al. Cabozantinib in patients with platinum-refractory metastatic urothelial carcinoma: an open-label, single-centre, phase 2 trial. Lancet Oncol. 21, 1099\u20131109 (2020).","journal-title":"Lancet Oncol."},{"key":"922_CR50","doi-asserted-by":"publisher","unstructured":"Apolo, A. B. et al. Final results from a phase I trial and expansion cohorts of cabozantinib and nivolumab alone or with ipilimumab for advanced\/metastatic genitourinary tumors. J. Clin. Oncol. https:\/\/doi.org\/10.1200\/jco.23.02233 (2024).","DOI":"10.1200\/jco.23.02233"},{"key":"922_CR51","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-016-1070-5","volume":"17","author":"E Becht","year":"2016","unstructured":"Becht, E. et al. Estimating the population abundance of tissue-infiltrating immune and stromal cell populations using gene expression. Genome Biol. 17, 218 (2016).","journal-title":"Genome Biol."},{"key":"922_CR52","doi-asserted-by":"publisher","first-page":"1906","DOI":"10.1038\/sj.bjc.6601400","volume":"89","author":"EJ Bromwich","year":"2003","unstructured":"Bromwich, E. J. et al. The relationship between T-lymphocyte infiltration, stage, tumour grade and survival in patients undergoing curative surgery for renal cell cancer. Br. J. Cancer 89, 1906\u20131908 (2003).","journal-title":"Br. J. Cancer"},{"key":"922_CR53","doi-asserted-by":"publisher","first-page":"3031","DOI":"10.1158\/1078-0432.CCR-14-2926","volume":"21","author":"NA Giraldo","year":"2015","unstructured":"Giraldo, N. A. et al. Orchestration and prognostic significance of immune checkpoints in the microenvironment of primary and metastatic renal cell cancer. Clin. Cancer Res. 21, 3031\u20133040 (2015).","journal-title":"Clin. Cancer Res."},{"key":"922_CR54","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1016\/j.ccell.2020.10.011","volume":"38","author":"RJ Motzer","year":"2020","unstructured":"Motzer, R. J. et al. Molecular subsets in renal cancer determine outcome to checkpoint and angiogenesis blockade. Cancer Cell 38, 803\u2013817 e804 (2020).","journal-title":"Cancer Cell"},{"key":"922_CR55","first-page":"5132","volume":"61","author":"O Nakano","year":"2001","unstructured":"Nakano, O. et al. Proliferative activity of intratumoral CD8(+) T-lymphocytes as a prognostic factor in human renal cell carcinoma: clinicopathologic demonstration of antitumor immunity. Cancer Res. 61, 5132\u20135136 (2001).","journal-title":"Cancer Res."},{"key":"922_CR56","doi-asserted-by":"crossref","unstructured":"Saliby, R. M. et al. Impact of renal cell carcinoma molecular subtypes on immunotherapy and targeted therapy outcomes. Cancer Cell 42, 732\u2013735 (2024).","DOI":"10.1016\/j.ccell.2024.03.002"},{"key":"922_CR57","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1093\/annonc\/mdu184","volume":"25","author":"TK Choueiri","year":"2014","unstructured":"Choueiri, T. K. et al. A phase I study of cabozantinib (XL184) in patients with renal cell cancer. Ann. Oncol. 25, 1603\u20131608 (2014).","journal-title":"Ann. Oncol."},{"key":"922_CR58","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1097\/01.sla.0000133083.54934.ae","volume":"240","author":"D Dindo","year":"2004","unstructured":"Dindo, D., Demartines, N. & Clavien, P. A. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann. Surg. 240, 205\u2013213 (2004).","journal-title":"Ann. Surg."},{"key":"922_CR59","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer, E. A. et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur. J. Cancer 45, 228\u2013247 (2009).","journal-title":"Eur. J. Cancer"},{"key":"922_CR60","doi-asserted-by":"publisher","first-page":"3539","DOI":"10.1158\/1078-0432.CCR-17-3831","volume":"24","author":"JI Odegaard","year":"2018","unstructured":"Odegaard, J. I. et al. Validation of a plasma-based comprehensive cancer genotyping assay utilizing orthogonal tissue- and plasma-based methodologies. Clin. Cancer Res. 24, 3539\u20133549 (2018).","journal-title":"Clin. Cancer Res."}],"container-title":["Nature Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s43018-025-00922-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43018-025-00922-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43018-025-00922-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,30]],"date-time":"2025-03-30T16:31:05Z","timestamp":1743352265000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s43018-025-00922-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,27]]},"references-count":60,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,3]]}},"alternative-id":["922"],"URL":"https:\/\/doi.org\/10.1038\/s43018-025-00922-5","relation":{},"ISSN":["2662-1347"],"issn-type":[{"value":"2662-1347","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,27]]},"assertion":[{"value":"20 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"M.A.B. has acted as a paid consultant for and\/or as a member of the advisory boards of Exelixis, Bayer, BMS, Eisai, Pfizer, AstraZeneca, Janssen, Calithera Biosciences, Genomic Health, Nektar, EMD Serono, SeaGen and Sanofi and his institution has received grants from Merck, Xencor, Bayer, Bristol Myers Squibb, Genentech\/Roche, SeaGen, Incyte, Nektar, AstraZeneca, Tricon Pharmaceuticals, Exelixis, Nikang, Loxo Oncology, Ambrx, Regeneron, Acrivon Therapeutics, Amgen, Genome & Company, AAA, Peloton Therapeutics and Pfizer for work performed outside of the current study. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}